Jolly Mazumdar, PhD, MBA, is a Biotech Entrepreneur with 13+ years of drug discovery and development experience spanning big pharma and biotech.
Jolly co-founded Chimeron Bio, a leading-edge RNA biotech based in Philadelphia, PA, and was the Company’s President, Board Member and CEO from 2017-2022. Under her leadership, Chimeron developed a novel self-amplifying RNA technology platform for applications in Oncology, Infectious Diseases and Rare Gene Disorders. She built the foundational team and infrastructure and successfully transitioned the Company to its new management upon securing additional investment to enable the next phase of the Company growth- product development and advancement to the clinic.
Previously, Jolly was the clinical biomarker lead for Oncology at GSK where she was part of the clinical development leadership team to win accelerated approvals for targeted melanoma drugs Tafinlar and Mekinist, and Blenrep, the first antibody-drug conjugate targeting BCMA therapy for multiple myeloma. Her experience spans Phase-1 through post-marketing studies for small molecules, biologics and epigenetic modifiers. She also has experience with Companion Diagnostics.
Jolly conducted her post-doctoral training at the University of Pennsylvania after completing her Ph.D. at the University of Georgia. She holds an M.B.A. from the Columbia Business School. She is deeply passionate about new technology development for smart medicines, the Philadelphia life science ecosystem and advancing women in science and entrepreneurship.
